Drug Type: Small Molecule
Conditions: ALS, diabetes, retinitis pigmentosa
Mechanism Type: Unfolded protein response (UPR), IRE1 alpha inhibitor
Mechanism: OptiKira is developing inhibitors of the unfolded protein response, specifically of inositol-requiring enzyme-1 alpha (IRE1α), a key activation step in the unfolded protein response (UPR). The technology has applications for ALS, although the company’s current focus is diabetes and retinitis pigementosa.
U.S. Status for ALS: Preclinical
 OptiKira, a New Biotech Start-up, Created to Develop Drugs to Prevent Cell Death Caused by the Unfolded Protein Response. PR Newswire, 2 Feb 2015. Accessed 11 Mar 2016 from http://www.prnewswire.com/news-releases/optikira-a-new-biotech-start-up-created-to-develop-drugs-to-prevent-cell-death-caused-by-the-unfolded-protein-response-300028909.html.
Last updated March 11th, 2019